Skip to content

Usefulness of Pulsed Inhaled Nitric OXide (iNO) in adults with asymptomatic or mildly symptomatic COVID patients without pre-existing illness.

Efficacy of Pulsed Inhaled Nitric OXide (iNO) in adults with asymptomatic or mildly symptomatic COVID patients without co-morbidities (EPINOX study). A single centre, academic, prospective, case control, non-randomized, open labelled, interventional, comparative study - EPINOX

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033771
Enrollment
250
Registered
2021-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B338- Other specified viral diseases

Interventions

Intervention1: pulsed inhaled nitric oxide: Administer pulsed inhaled nitric oxide at 160 ppm for 30 mins once a day for 5 days Control Intervention1: Room air: Subjects who shall not be administered

Sponsors

Sir h n Reliance Foundation hospital and research centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults, 18 â?? 50 years(account for 60% of cases in India as on May 6, 2021), with positive rtPCR and consenting to the study within 48 hours of diagnosis, already admitted or willing to get admitted to the COVID facility at SevenHills Hospital, managed by Sir H N Reliance Foundation Hospital, with asymptomatic or mildly symptomatic symptoms.

Exclusion criteria

Exclusion criteria: A.Comorbid factors: 1. Smoker 2. Hypertension or hypotension 3. Diabetes Mellitus 4. Renal injury or failure 5. Known abnormal Haemoglobinopathies 6. Known clinically significant Pulmonary Arterial Hypertension 7. Known congenital heart disease operated or otherwise 8. Heart Failure (LVF B.Other factors: 1. Additional treatment with Steroids, Tocilizumab, Plasma therapy. 2. Requiring supplemental oxygen to maintain saturations > 93% 3. Needing intubation and mechanical ventilation 4. Past history of documented COVID-19 infection 5. Completed COVID vaccination. 6. Pregnant women, confirmed or suspected 7. Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study 8. Current smoker - Current smokerâ?? is someone who has smoked greater than 100 cigarettes in their lifetime and has smoked in the last 28 days.

Design outcomes

Primary

MeasureTime frame
1. Number of days to negative rtPCR or decrease viral load reflected in the ct values 35 2. Number of patients in room air progressing to O2 supplementation, or further advanced medications or ventilation in first 10 days. 3. Reduction in number of hospital days 4. Reduction in Morbidity and mortality. Timepoint: 3 months trial and data collection 3 months data analysis

Secondary

MeasureTime frame
1. To compare the change in ct values between the 2 groups 2. Number of subjects who progressed to supplemental oxygen therapy 3. Number of subjects who progressed to any form of ventilation 4. Duration of hospitalization compared in both groups. 5. Number of subjects in the intervention group who had significant adverse reactions 6. Mortality rates in both group. Timepoint: 3 months to collect data of patients # months to analyze the data

Countries

India

Contacts

Public ContactNiranjan Waje

Sir H N Reliance Foundation Hospital and Research Centre

rfh.academics@rfhospital.org26135326

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026